Celcuity/CELC

$17.98

2.51%
-
1D1W1MYTD1YMAX

About Celcuity

Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.

Ticker

CELC

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Brian Sullivan

Employees

55

Headquarters

Minneapolis, United States

Celcuity Metrics

BasicAdvanced
$525.01M
Market cap
-
P/E ratio
-$2.70
EPS
0.85
Beta
-
Dividend rate
$525.01M
0.84857
$22.19
$8.39
217.2K
13.433
26.498
26.498
-34.76%
-46.63%
-36.88%
3.146
3.756
-3.21%

What the Analysts think about Celcuity

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 5 analysts.
59.07% upside
High $40.00
Low $24.00
$17.98
Current price
$28.60
Average price target

Celcuity Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-18.8M
2.17%
Profit margin
0%
-

Celcuity Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 10.76%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.55
-$0.66
-$0.83
-$0.65
-
Expected
-$0.52
-$0.60
-$0.68
-$0.73
-$0.71
Surprise
6.28%
10.46%
21.61%
-10.76%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Celcuity stock?

Celcuity (CELC) has a market cap of $525.01M as of April 23, 2024.

What is the P/E ratio for Celcuity stock?

The price to earnings (P/E) ratio for Celcuity (CELC) stock is 0 as of April 23, 2024.

Does Celcuity stock pay dividends?

No, Celcuity (CELC) stock does not pay dividends to its shareholders as of April 23, 2024.

When is the next Celcuity dividend payment date?

Celcuity (CELC) stock does not pay dividends to its shareholders.

What is the beta indicator for Celcuity?

Celcuity (CELC) has a beta rating of 0.85. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Celcuity stock price target?

The target price for Celcuity (CELC) stock is $28.6, which is 59.07% above the current price of $17.98. This is an average based on projections from 5 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Celcuity stock

Buy or sell Celcuity stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing